Bioadhesion of hydrated chitosans: An in vitro and in vivo study

Henriksen, Ingrid; Green, Keith L.; Smart, John D.; Smistad, Gro; Karlsen, Jan

doi:10.1016/s0378-5173(96)04776-x

Cited by 193 publications

(78 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chitosan is often used in drug delivery formulations as a permeation enhancer due to its mucoadhesive properties, which are attributed to its cationic polyelectrolyte structure allowing it to bind to negatively charged cell surfaces [48]. Chitosan coating or integration onto the surface of the drug carrier enhances its interaction with the cell membrane, thereby promoting cellular uptake [49] .…”

Section: Iron Absorption From Ascorbyl Palmitate Nanocarriersmentioning

confidence: 99%

Ascorbyl palmitate/DSPE-PEG nanocarriers for oral iron delivery: Preparation, characterisation and in vitro evaluation

Zariwala

Farnaud

Merchant

et al. 2014

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

Section: Iron Absorption From Ascorbyl Palmitate Nanocarriersmentioning

confidence: 99%

Ascorbyl palmitate/DSPE-PEG nanocarriers for oral iron delivery: Preparation, characterisation and in vitro evaluation

Zariwala

Farnaud

Merchant

et al. 2014

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

“…Mucoadhesive microspheres/microparticles have advantages such as efficient absorption and enhanced bioavailability of drugs owing to a high surface-to--volume ratio, a much more intimate contact with the mucus layer, and specific targeting of drugs to the absorption site (11)(12)(13)(14).…”

mentioning

confidence: 99%

Formulation and in vitro characterization of spray dried microspheres of amoxicillin

Raval¹,

Patel²,

Patel³

2010

Acta Pharmaceutica

View full text Add to dashboard Cite

Amoxicillin is a semi-synthetic, orally absorbed, broad-spectrum antibiotic. It is still widely used in the standard eradication treatment of gastric and duodenal ulcers, which are associated with Helicobacter pylori infection, combined with a second antibiotic and an acid-suppressing agent (1, 2). H. pylori, a prevalent human-specific pathogen, is a causative agent in chronic active gastritis (3), gastric and duodenal ulcers (4) and gastric adenocarcinoma (5), one of the most common forms of cancer in humans. The mechanisms by which H. pylori may cause gastroduodenal disease and contribute to gastric carcinogenesis are still hypothetical.Treatment of H. pylori remains a challenging proposition. One reason for incomplete eradication of H. pylori is probably the short residence time of the dosage form in the stomach so that effective antimicrobial concentration cannot be achieved in the gastric The purpose of the present study was to design mucoadhesive chitosan microspheres containing amoxicillin. Chitosan microspheres with a small particle size and good sphericity were prepared by a spray-drying method followed by chemical treatment with a chemical crosslinking agent (glutaraldehyde). Parameters affecting the crosslinking extent of the crosslinking time and the concentration of the crosslinker agent. Crosslinked spray-dried chitosan microspheres were analyzed for their morphological aspects, particle size, drug entrapment efficiency, swelling percent and in vitro drug release. Batch M4 with a drug polymer ratio of 1:2, dissolved in minimum concentration of acetic acid solution treated with glutraldehyde, was found to be optimal giving controlled drug release for 10 h. It was found that both the increase of glutaraldehyde concentration and crosslinking duration decreased the swelling capacity of chitosan microspheres. This could be directly correlated to drug release from the microspheres.

show abstract

“…In the context of drug delivery, this can be defined as the adhesion of an artificial material (such as a polymer system) to a biological substrate material 60 . We assessed the mucoadhesion of optimized formulations using an inclined-plate method in the presence and absence of mucin 24 , with mucoadhesion assumed to have occurred if the displacement of the formulation in the absence of mucin is greater than in the presence of mucin.…”

Section: In-vitro Mucoadhesionmentioning

confidence: 99%

Development and Evaluation of a Novel Intranasal Spray for the Delivery of Amantadine

Lungare

Bowen

Badhan

2016

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

The aim of this study was to develop and characterise an intranasal delivery system for amantadine (AMT). Optimal formulations (F) consisted of a thermosensitive polymer Pluronic ® 127 (P127) and either carboxy methyl cellulose (CMC) or chitosan (CS) which demonstrated gel-transition at nasal cavity temperatures (34 °C ± 1 °C). Rheologically, the loss tangent (Tan δ) confirmed a three-stage gelation phenomena at 34 °C ± 1 °C and nonNewtonian behaviour. Storage of FCMC and FCS at 4 °C for 8 weeks resulted in repeatable release profiles at 34 °C when sampled, with a Fickian mechanism earlier on but moving towards anomalous transport by week 8. Polymers (P127, CMC and CS) demonstrated no significant cellular toxicity to human nasal epithelial cells up to 4 mg/mL and up to 1 mM for AMT (IC50: 4.5 mM ± 0.05 mM). FCMC and FCS demonstrated slower release across an in-vitro human nasal airway model (43-44 % vs 79 % ± 4.58 % for AMT). Using a human nasal cast model, deposition into the olfactory regions (potential nose-to-brain) was demonstrated upon nozzle insertion (5 mm) whereas tilting of the head forward (15°) resulted in greater deposition in the bulk of the nasal cavity. KEYWORDSParkinson's disease; rheology; nasal; RPMI 2650; nose to brain; thermoresponsive; 3 INTRODUCTION Parkinson's disease (PD) is an ageing associated progressive neurological disorder and affects 1.5 % of the population over 65-years of age 1 , with age-adjusted prevalence rates thought to be around 150 per 100,000 with a suggested mean onset in the 70's 1 . Ageing is the largest single risk factor for the development of PD and the pathogenesis of PD is composed of a range of events leading towards neuronal apoptosis, primarily of degradation of dopamine neurones in the sustantia nigra. The mainstay of clinical drug therapy focuses on increases the levels of dopamine (DA) in the brain, with oral dosing of levodopa being the most commonly used to pharmacological intervention treatment to reverse the symptoms of PD. It is also common to use adjunct therapies in conjunction with levodopa, such as the weak NMDA-type receptor antagonist amantadine, which can aid in blocking dopamine reuptake.

show abstract

Bioadhesion of hydrated chitosans: An in vitro and in vivo study

Cited by 193 publications

References 23 publications

Ascorbyl palmitate/DSPE-PEG nanocarriers for oral iron delivery: Preparation, characterisation and in vitro evaluation

Ascorbyl palmitate/DSPE-PEG nanocarriers for oral iron delivery: Preparation, characterisation and in vitro evaluation

Formulation and in vitro characterization of spray dried microspheres of amoxicillin

Development and Evaluation of a Novel Intranasal Spray for the Delivery of Amantadine

Contact Info

Product

Resources

About